Skip to main content
Fig. 5 | Journal of Experimental & Clinical Cancer Research

Fig. 5

From: A novel M phase blocker, DCZ3301 enhances the sensitivity of bortezomib in resistant multiple myeloma through DNA damage and mitotic catastrophe

Fig. 5

Synergistic effect of DCZ3301 and BTZ in MM cell lines. Effect of treatment with BTZ alone- or in combination with different doses of DCZ3301 on cell growth in NCI-H929S (a), RPMI-8226 (b), NCI-H929R (c), and RPMI-8226R5 (d) cells. Combination index (CI) for two drugs in the MM cell lines. CI value < 1 represents synergistic. Data were expressed as mean ± SD. (e and f) Cell cycle analysis of BTZ-resistant MM cells treated with DCZ3301 alone, BTZ alone, and in combination with DCZ3301. (g) Western blot of G2/M phase related proteins in NCI-H929R and RPMI-8226R5 cells treated with DCZ3301 alone, BTZ alone and their combination for 48 h

Back to article page